Black Diamond Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Black Diamond Therapeutics reports a net loss of $9.0 million for Q1 2026, with cash reserves projected to fund operations into the second half of 2028.
NASDAQ
Black Diamond Therapeutics reported a net income of $37.5 million for the nine months ended September 30, 2025, driven by a $70 million upfront payment from its global licensing agreement with Servier for BDTX-4933, while continuing to advance its lead oncology candidate, silevertinib.
NASDAQ
Black Diamond Therapeutics reported a significant financial turnaround in Q2 2025, driven by a $70 million licensing deal and operational efficiencies, extending its cash runway into Q4 2027.
NASDAQ
10-Q: Black Diamond Therapeutics Reports Q1 2025 Results, Fueled by $70M Licensing Deal with Servier
Black Diamond Therapeutics posts a profitable first quarter in 2025, driven by a significant licensing agreement with Servier for BDTX-4933.
NASDAQ
Black Diamond Therapeutics reported its Q3 2024 financial results and announced a corporate restructuring to prioritize its lead program, BDTX-1535.
NASDAQ
Black Diamond Therapeutics reports a net loss of $19.9 million for the second quarter of 2024, while advancing its clinical programs for BDTX-1535 and BDTX-4933.
NASDAQ
Black Diamond Therapeutics reported a net loss of $18.2 million for the first quarter of 2024, while providing updates on its clinical programs for BDTX-1535 and BDTX-4933.